Covered recipient · General Payments record
PAUL GETZ
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$161.56
8 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $161.56 | 8 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $56.07 | 3 |
| Lilly USA, LLC | $39.59 | 2 |
| Regeneron Healthcare Solutions, Inc. | $27.69 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $24.03 | 1 |
| Novartis Pharmaceuticals Corporation | $14.18 | 1 |
Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PAUL GETZ
NPI 1508866443 · CMS profile ID 249750
Allopathic & Osteopathic Physicians / Dermatology
WEST DUNDEE, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
8 matching records · $161.56 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–8 of 8.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $18.57 | 12/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719348743 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.69 | 11/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724423547 | CMS |
| Lilly USA, LLC | $15.85 | 10/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728587957 | CMS |
| Janssen Biotech, Inc. | $22.46 | 09/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719348741 | CMS |
| Lilly USA, LLC | $23.74 | 07/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728577909 | CMS |
| Novartis Pharmaceuticals Corporation | $14.18 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725751795 | CMS |
| Janssen Biotech, Inc. | $15.04 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719348739 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $24.03 | 01/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737461925 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $9,013.60 | 1 |
| PY2025 | Principal investigator | $446,834.92 | 130 |
| PY2024 | Recipient | $7,087.86 | 1 |
| PY2024 | Principal investigator | $650,362.14 | 156 |
| PY2023 | Recipient | $10,934.40 | 2 |
| PY2023 | Principal investigator | $209,903.19 | 44 |
| PY2022 | Principal investigator | $139,606.12 | 29 |
| PY2021 | Recipient | $11,617.83 | 3 |
| PY2021 | Principal investigator | $358,649.13 | 52 |
| PY2020 | Principal investigator | $277,127.30 | 39 |
| PY2019 | Principal investigator | $329,491.24 | 41 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
131 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $3,413.00 | 12/22/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175360603 |
| Principal investigator 1 | Incyte Corporation | $3,852.00 | 12/19/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531386 |
| Principal investigator 1 | Incyte Corporation | $1,058.20 | 12/08/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531405 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531425 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531437 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531441 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531444 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531457 |
| Principal investigator 1 | Incyte Corporation | $4,586.30 | 11/26/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531364 |
| Principal investigator 1 | Incyte Corporation | $3,486.60 | 11/26/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531376 |
| Principal investigator 1 | Incyte Corporation | $4,834.80 | 11/26/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531380 |
| Principal investigator 1 | Incyte Corporation | $2,277.90 | 11/24/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531432 |
| Principal investigator 1 | Incyte Corporation | $4,095.00 | 11/06/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531371 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531390 |
| Principal investigator 1 | Incyte Corporation | $2.12 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531393 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531398 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531402 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531409 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531412 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531416 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531421 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531448 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 11/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531451 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 11/03/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360568 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity Dundee Dermatology | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235997589 |
| Principal investigator 1 | PFIZER INC. | $2,132.00 | 10/04/2025 | Non-covered Recipient Entity Dundee Dermatology | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228825635 |
| Principal investigator 1 | Incyte Corporation | $1,652.40 | 10/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531360 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 10/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531357 |
| Principal investigator 1 | Incyte Corporation | $6,694.20 | 09/23/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531307 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 09/16/2025 | Non-covered Recipient Entity Dr. Paul Getz | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175215982 |
| Principal investigator 1 | Incyte Corporation | $1,231.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531312 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531317 |
| Principal investigator 1 | Incyte Corporation | $2,900.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531321 |
| Principal investigator 1 | Incyte Corporation | $104.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531330 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531333 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531337 |
| Principal investigator 1 | Incyte Corporation | $15,000.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531349 |
| Principal investigator 1 | Incyte Corporation | $768.00 | 09/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531353 |
| Principal investigator 1 | Incyte Corporation | $3,104.10 | 09/11/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531303 |
| Principal investigator 1 | Incyte Corporation | $3,486.60 | 08/26/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531294 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 08/22/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531341 |
| Principal investigator 1 | Incyte Corporation | $1,577.70 | 08/20/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531325 |
| Principal investigator 1 | Incyte Corporation | $3,347.10 | 08/07/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531299 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,817.00 | 08/04/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175360506 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,444.00 | 08/01/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360561 |
| Principal investigator 1 | Incyte Corporation | $1,153.80 | 07/17/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531283 |
| Principal investigator 1 | Incyte Corporation | $1,743.30 | 07/10/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531288 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 07/01/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531345 |
| Principal investigator 1 | Incyte Corporation | $707.00 | 06/25/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531249 |
| Principal investigator 1 | Incyte Corporation | $1,919.00 | 06/25/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531253 |
| Principal investigator 1 | Incyte Corporation | $1,289.20 | 06/25/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531261 |
| Principal investigator 1 | Incyte Corporation | $1,753.00 | 06/25/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531265 |
| Principal investigator 1 | Incyte Corporation | $15,450.00 | 06/20/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531257 |
| Principal investigator 1 | Incyte Corporation | $3,090.00 | 06/20/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531274 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 06/19/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531240 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 06/05/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531245 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,521.69 | 06/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190310420 |
| Principal investigator 1 | Incyte Corporation | $576.90 | 05/27/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531236 |
| Principal investigator 1 | Janssen Research & Development, LLC | $396.00 | 05/27/2025 | Non-covered Recipient Entity Dr. Paul Getz | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175215977 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,726.00 | 05/27/2025 | Non-covered Recipient Entity Dr. Paul Getz | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175215998 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,170.00 | 05/26/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,838.00 | 05/09/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175360539 |
| Principal investigator 1 | Incyte Corporation | $1,153.80 | 05/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531231 |
| Principal investigator 1 | Eli Lilly and Company | $18,869.34 | 04/29/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187890430 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,745.00 | 04/28/2025 | Non-covered Recipient Entity Dr. Paul Getz | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175215971 |
| Principal investigator 1 | Amgen Inc. | $14,000.00 | 04/23/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) | No dispute reported | 06/30/2026 | 1246646378 |
| Principal investigator 1 | Amgen Inc. | $24,897.00 | 04/23/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246646383 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,500.00 | 04/15/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1190310418 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 04/10/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531207 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 04/10/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531211 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 04/10/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531219 |
| Principal investigator 1 | Incyte Corporation | $15,000.00 | 04/10/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531222 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 04/10/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531227 |
| Principal investigator 1 | Incyte Corporation | $2,423.70 | 04/09/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531269 |
| Principal investigator 1 | Incyte Corporation | $576.90 | 04/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531215 |
| Principal investigator 1 | Incyte Corporation | $12.36 | 04/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,859.00 | 03/24/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360587 |
| Principal investigator 1 | Incyte Corporation | $3,043.80 | 03/20/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $43,316.00 | 03/20/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175360515 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,685.48 | 03/15/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190302597 |
| Principal investigator 1 | Incyte Corporation | $3,620.70 | 03/14/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,253.00 | 03/14/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360531 |
| Principal investigator 1 | Incyte Corporation | $1,707.30 | 03/12/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,487.00 | 03/07/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175360522 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38,468.00 | 03/07/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360547 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,404.00 | 03/06/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175360577 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531111 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531118 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531123 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531127 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531137 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531141 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531145 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531149 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531152 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531190 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531194 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531198 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,874.00 | 03/03/2025 | Non-covered Recipient Entity Dr. Paul Getz | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175215992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,627.00 | 02/07/2025 | Non-covered Recipient Entity PAUL GETZ MD SC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175360554 |
| Principal investigator 1 | Incyte Corporation | $3,043.80 | 02/06/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531469 |
| Principal investigator 1 | Incyte Corporation | $576.90 | 01/29/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531462 |
| Principal investigator 1 | Amgen Inc. | $6,514.34 | 01/21/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640969 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $9,013.60 | 01/17/2025 | Covered Recipient Physician | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1236002257 |
| Principal investigator 1 | Incyte Corporation | $1,707.30 | 01/15/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531170 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $149.47 | 01/15/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1190302595 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 01/03/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240531465 |
| Principal investigator 1 | Incyte Corporation | $307.40 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531050 |
| Principal investigator 1 | Incyte Corporation | $90.10 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531054 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531057 |
| Principal investigator 1 | Incyte Corporation | $201.40 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531061 |
| Principal investigator 1 | Incyte Corporation | $275.60 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531065 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531070 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531073 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531077 |
| Principal investigator 1 | Incyte Corporation | $53.80 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531081 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531085 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531088 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531093 |
| Principal investigator 1 | Incyte Corporation | $90.10 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531098 |
| Principal investigator 1 | Incyte Corporation | $74.20 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531101 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531106 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531114 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531132 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531157 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531161 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531165 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531174 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531176 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531181 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity DUNDEE DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240531202 |